CA2900782C - Methods and diets to protect against chemotoxicity and age related illnesses - Google Patents

Methods and diets to protect against chemotoxicity and age related illnesses Download PDF

Info

Publication number
CA2900782C
CA2900782C CA2900782A CA2900782A CA2900782C CA 2900782 C CA2900782 C CA 2900782C CA 2900782 A CA2900782 A CA 2900782A CA 2900782 A CA2900782 A CA 2900782A CA 2900782 C CA2900782 C CA 2900782C
Authority
CA
Canada
Prior art keywords
protein
diet
igf
calories
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2900782A
Other languages
English (en)
French (fr)
Other versions
CA2900782A1 (en
Inventor
Valter D. Longo
Sebastian BRANDHORST
Morgan Elyse Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CA2900782A1 publication Critical patent/CA2900782A1/en
Application granted granted Critical
Publication of CA2900782C publication Critical patent/CA2900782C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pediatric Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
CA2900782A 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses Active CA2900782C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
US61/763,797 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Publications (2)

Publication Number Publication Date
CA2900782A1 CA2900782A1 (en) 2014-08-21
CA2900782C true CA2900782C (en) 2022-09-27

Family

ID=51297596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900782A Active CA2900782C (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Country Status (12)

Country Link
US (3) US9237761B2 (enExample)
EP (2) EP3510875B1 (enExample)
JP (2) JP6885671B2 (enExample)
KR (1) KR20150124962A (enExample)
CN (3) CN109187991B (enExample)
AU (3) AU2014216349B2 (enExample)
BR (1) BR112015019223A2 (enExample)
CA (1) CA2900782C (enExample)
ES (1) ES2807781T3 (enExample)
MX (1) MX382484B (enExample)
RU (2) RU2674681C2 (enExample)
WO (1) WO2014127000A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909802B1 (en) * 2012-10-22 2020-08-12 University of Southern California Diet formulations promoting tissue/organ regeneration
ES2807781T3 (es) * 2013-02-12 2021-02-24 Univ Southern California Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1
CN114052245A (zh) * 2013-07-01 2022-02-18 南加利福尼亚大学 膳食包装
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944479C (en) 2014-04-02 2023-02-21 University Of Southern California Dietary formulation and method for treating autoimmune and inflammatory diseases
KR20180016333A (ko) 2015-02-12 2018-02-14 유니버시티 오브 써던 캘리포니아 질환 예방 및 치료에서의 성장 호르몬 수용체의 차단제
CA3108664A1 (en) * 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
MX2018009849A (es) 2016-02-15 2018-11-09 Univ Southern California Combinaciones de farmacos y metodos para estimular regeneracion de tipo embrionaria para tratar diabetes y otras enfermedades.
AU2017261723B2 (en) * 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
US11504408B2 (en) * 2018-03-15 2022-11-22 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
ES2992080T3 (es) * 2018-06-07 2024-12-09 Nestle Sa Métodos y composiciones para incrementar los cuerpos cetónicos en animales
WO2020015842A1 (en) 2018-07-18 2020-01-23 Michalsen Andreas Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
JP2020059699A (ja) * 2018-10-04 2020-04-16 株式会社明治 難治性癌の食事療法およびそれに適した治療食
CN113301807A (zh) 2018-11-09 2021-08-24 L·纽乐股份有限公司 间歇性禁食模仿的营养棒
EP3963599A4 (en) * 2019-04-30 2023-01-18 University of Southern California FASTING DIET AS AN INTERVENTION IN ALZHEIMER'S DISEASE
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
EP4076458A1 (en) * 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
IT202000008740A1 (it) 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
EP4190173B1 (en) * 2020-09-23 2024-07-17 Aminovita S.L. Metabolic cancer therapy
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
US20250194656A1 (en) * 2023-12-14 2025-06-19 L-Nutra Inc. Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
WO2002103031A2 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
BRPI0519507A2 (pt) * 2004-12-27 2009-03-10 Nestec Sa uso de fàrmula lactente com teor de proteÍna reduzido
CN101378771B (zh) * 2006-02-01 2012-11-21 雀巢技术公司 用于延长寿命的营养系统和方法
ES2800327T3 (es) * 2008-04-24 2020-12-29 Univ Of Southern California Usc Stevens Composiciones dietéticas y métodos de protección contra la quimioterapia o radioterapia
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
PL2490684T3 (pl) * 2009-10-22 2018-07-31 University Of Southern California Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu
EP2909802B1 (en) * 2012-10-22 2020-08-12 University of Southern California Diet formulations promoting tissue/organ regeneration
ES2807781T3 (es) * 2013-02-12 2021-02-24 Univ Southern California Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1

Also Published As

Publication number Publication date
CA2900782A1 (en) 2014-08-21
HK1212028A1 (en) 2016-06-03
AU2020200297A1 (en) 2020-02-06
JP2016509994A (ja) 2016-04-04
KR20150124962A (ko) 2015-11-06
CN105008929B (zh) 2018-10-02
BR112015019223A2 (pt) 2017-07-18
JP2020073473A (ja) 2020-05-14
EP3510875B1 (en) 2020-06-10
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
RU2674681C2 (ru) 2018-12-12
US20140227373A1 (en) 2014-08-14
AU2020200297B2 (en) 2022-04-07
CN109187991B (zh) 2021-12-24
US20170035094A1 (en) 2017-02-09
US9237761B2 (en) 2016-01-19
EP2956776A2 (en) 2015-12-23
RU2018141475A3 (enExample) 2022-03-29
MX382484B (es) 2025-03-13
EP3510875A1 (en) 2019-07-17
CN109187991A (zh) 2019-01-11
RU2015134780A (ru) 2017-03-20
CN105008929A (zh) 2015-10-28
ES2807781T3 (es) 2021-02-24
JP6885671B2 (ja) 2021-06-16
US20160331016A1 (en) 2016-11-17
CN114236130A (zh) 2022-03-25
EP2956776A4 (en) 2016-12-21
AU2022202764A1 (en) 2022-05-19
AU2014216349A1 (en) 2015-08-06
AU2014216349B2 (en) 2019-10-24
WO2014127000A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
AU2020200297B2 (en) Methods and diets to protect against chemotoxicity and age related illnesses
US20240298689A1 (en) Fasting condition as dietary treatment of diabetes
Brandhorst et al. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression
US20210137856A1 (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
AU2017207370B2 (en) Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
HK40002950A (en) Method for providing reasonable protein diet to subject
HK1212028B (en) Methods and diets to protect against chemotoxicity and age related illnesses
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180802

EEER Examination request

Effective date: 20180802